EA202092964A1 - Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака - Google Patents

Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака

Info

Publication number
EA202092964A1
EA202092964A1 EA202092964A EA202092964A EA202092964A1 EA 202092964 A1 EA202092964 A1 EA 202092964A1 EA 202092964 A EA202092964 A EA 202092964A EA 202092964 A EA202092964 A EA 202092964A EA 202092964 A1 EA202092964 A1 EA 202092964A1
Authority
EA
Eurasian Patent Office
Prior art keywords
platinum
cancer
antineoplastic agents
basis
treatment
Prior art date
Application number
EA202092964A
Other languages
English (en)
Russian (ru)
Inventor
Жоан Сеоане Суарез
Джудит Анидо Фолгуэйра
Робин Мэттью Халлетт
Патрисиа Энн Гиблин
Жанн Маграм
Наимиш Пандйа
Роберт Вассерман
Ангус Синклер
Original Assignee
Медиммун Лимитед
Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн
Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед, Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн, Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс filed Critical Медиммун Лимитед
Publication of EA202092964A1 publication Critical patent/EA202092964A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202092964A 2018-06-18 2019-06-17 Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака EA202092964A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382432 2018-06-18
PCT/IB2019/000812 WO2019243900A2 (en) 2018-06-18 2019-06-17 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Publications (1)

Publication Number Publication Date
EA202092964A1 true EA202092964A1 (ru) 2021-03-30

Family

ID=62837845

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092964A EA202092964A1 (ru) 2018-06-18 2019-06-17 Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака

Country Status (12)

Country Link
US (1) US20210187106A1 (https=)
EP (1) EP3806899A2 (https=)
JP (2) JP7379390B2 (https=)
KR (1) KR20210022065A (https=)
CN (1) CN112955178B (https=)
AU (2) AU2019291307B2 (https=)
CA (1) CA3103369A1 (https=)
EA (1) EA202092964A1 (https=)
IL (1) IL279444A (https=)
MA (1) MA52300A (https=)
SG (1) SG11202012576QA (https=)
WO (1) WO2019243900A2 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
CN107624071A (zh) 2015-04-17 2018-01-23 诺福泰克公司 肺癌治疗方法
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof

Also Published As

Publication number Publication date
CA3103369A1 (en) 2019-12-26
EP3806899A2 (en) 2021-04-21
JP2024023212A (ja) 2024-02-21
IL279444A (en) 2021-01-31
WO2019243900A2 (en) 2019-12-26
JP2021533084A (ja) 2021-12-02
US20210187106A1 (en) 2021-06-24
JP7603772B2 (ja) 2024-12-20
AU2019291307A1 (en) 2021-02-04
KR20210022065A (ko) 2021-03-02
AU2024204564A1 (en) 2024-07-18
JP7379390B2 (ja) 2023-11-14
WO2019243900A3 (en) 2020-03-05
AU2019291307B2 (en) 2024-04-04
MA52300A (fr) 2021-04-21
CN112955178B (zh) 2025-03-11
SG11202012576QA (en) 2021-01-28
CN112955178A (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
CY1125116T1 (el) Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2022005360A (es) Inhibidores de ras.
MX2022005359A (es) Inhibidores de ras.
MX2022005357A (es) Inhibidores de ras.
EA202191852A1 (ru) Необратимые ингибиторы взаимодействия менин-mll
CY1122243T1 (el) Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt
DK3902547T3 (da) Csf1r-hæmmere til anvendelse i cancerbehandling
MX2019013858A (es) Inhibidores de kras g12c y metodos para su uso.
MX391470B (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
DK3890740T3 (da) CD70 og venetoclax, en BCL-2 inhibitor, kombinationsterapi til behandling af akut myeloid leukæmi
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
EP4585273A3 (en) Mechanism of resistance to bet bromodomain inhibitors
MX2021006731A (es) Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
EA201890199A1 (ru) Комбинированная терапия для лечения гемобластозов и солидных опухолей
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
LT3962601T (lt) 5-ht2a agonistai, skirti panaudoti depresijos gydymui
ZA201904533B (en) Antibodies against lif and uses thereof
EA202091881A1 (ru) Соединения для лечения боли
IL289242A (en) Combination therapy methods, compositions and kits
EP3562803C0 (en) Notch inhibitors intended for use in the treatment of acute T-lymphoblastic leukemia
BR112022003670A2 (pt) Métodos de tratamento
JOP20210216A1 (ar) علاج السرطان